Value Investing Research & Market Analysis

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

0.6092 +0.0116 (+1.94%)
Delayed Quote Updated: 11:07 AM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
These stocks that are showing activity before the opening bell on Tuesday. ↗
Via Chartmill
News headline image
SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects
From SciSparc Ltd
Via GlobeNewswire
News headline image
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
These stocks are moving in today's after hours session ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio
From SciSparc Ltd
Via GlobeNewswire
News headline image
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Wednesday's pre-market session: top gainers and losers ↗
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
SciSparc Stock Soars Pre-Market After Snapping Up Patents For Next-Gen Endoscopy Tech ↗
In return, SciSparc shall issue to Xylo an amount of ordinary shares of the company. 
Via Stocktwits
Topics Intellectual Property
News headline image
SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems
From SciSparc Ltd
Via GlobeNewswire
News headline image
These stocks that are showing activity before the opening bell on Tuesday. ↗
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery
From SciSparc Ltd
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders
From SciSparc Ltd
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures ↗
SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio
From SciSparc Ltd
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
SciSparc And AutoMax Call Off Merger ↗
SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation. 
Via Benzinga
News headline image
SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors
From SciSparc Ltd
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.